Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery

OBJECTIVE: To evaluate the efficacy of an anterior chamber intracameral dexamethasone (ICD) drug-delivery suspension (Dexycu; EyePoint Pharmaceuticals, Watertown, Massachusetts, USA) providing sustained release of medication following a single application for the treatment of postoperative inflammat...

Descripción completa

Detalles Bibliográficos
Autor principal: Kiernan, Daniel F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228554/
https://www.ncbi.nlm.nih.gov/pubmed/32426525
http://dx.doi.org/10.1136/bmjophth-2020-000491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228554/
https://www.ncbi.nlm.nih.gov/pubmed/32426525
http://dx.doi.org/10.1136/bmjophth-2020-000491

Ejemplares similares